Encode ® Research Project
Sickle Cell & Thalassemia

The Quest for Integration

The science of nutrition and genetics has recently become a distinct discipline embraced by top genetic researchers worldwide. The triumph of molecular biology and its relation to nutrition and genetics has become the hope-chest of researchers who lead the quest to mitigate or control genetic polymorphisms known to shorten lifespan in humans.

Nutrients and foods can now be safely designed to encode transporters, receptors, carrier proteins, enzymes and hormones.

Graphic courtesy of: www.clarian.org

For NutraGenomic scientists, this means that they can begin to construct a picture of dietary interactions from the level of body composition and whole-body physiology, from substrate-flux through metabolic pathways, to the amount and activity of crucial enzymes, and on, down to the effects of gene expression.

The science of NutraGenomics focuses on polymorphisms in specific genes that encode particular receptors or transporters. This research impacts the development of new methodoligies in treating severe genetic diseases, such as Sickle Cell.

The model for nutritional genomics is the work that has already been done on drug-gene interactions, and the science of nutrition and genetics, NutraGenomics, has now joined in the search for new physiological systems that will impact genetic coding.

One of the major advances in NutraGenomics is the discovery of a new approach in the treatment of Sickle Cell disease and Thalassemia.

The scientific team at the Encode Research Project is a virtual Who’s-Who of physicians and researchers, including the world’s leading L-Arginine researcher and Patent holder, Dr. Ann de Wees Allen, along with her team, Clair Francomano, M.D., former Chief of Medical Genetics Branch at the National Institutes of Medicine (NIH), National Genome Research Institute, Chief of Human Genetics for the Laboratory of Genetics at the National Institute on Aging, and Dr. Randall Maxey, M.D. PhD., renowned cardiologist and former President of the National Medical Association, current Chief of Medicine, Encode Research Foundation for Ethnic-Related Diseases.

Graphic courtesy of: www.scdaamobile.org
The Encode Research Project ® has broken new ground in the field of genomics, and has, for the first time in the history of man, found a promising treatment for Sickle Cell Disease and Thalassemia, the number one genetic disease in the world.

The Encode Research Project ® has dedicated full resources, both scientific and monetary, to develop over the next decade, breakthrough Encoding Systems encompassing Nutrition and Genetics.

Team Director, Dr. Ann de Wees Allen received the first Glycemic Patent ever awarded worldwide, and went on to discover that L-Arginine is a Blind Amino Acid ®, receiving another Patent for L-Arginine biochemistry, with four Patents-Pending in the field of L-Arginine research.

With over 25-years of clinical research as Chief of Biomedical Research at the Glycemic Research Institute in Washington, D.C. (Glycemic.com), Dr. Allen conducts Human In Vivo Clinical Trials for the U.S. Government, as well as the largest food companies in the world, including Proctor & Gamble and Hershey Foods.

The goal of the Encode Research team is to “identify and develop tools that access signal-transduction pathways on a genomic-specific scale.” Their most recent work focuses on African-American variants that carry life-altering codes.

According to the Journal of the American Medical Association (JAMA), both Sickle Cell Disease and Thalassemia are related to Dysregulated Arginine Metabolism, which leads to dangerously low levels of serum L-Arginine, and its metabolite, Nitric Oxide (NO).

The free form amino acid, L-Arginine, is key in developing methods of treating Sickle Cell Disease and Thalassemia, which requires “jumping over” the Sickle Cell trail on human DNA. The Encode Research Team has broken the bounds of genetic research, discovering the first process for jumping-over the Sickle Cell & Thalassemia DNA polymorphism, and has filed Patents on this treatment.

Dr. Allen has named her genetic breakthrough “TLSV”, which stands for “The Louis Shapiro Variant”, named after a colleague of Dr. Allen’s in Washington, D.C., who believed in her research, and supported her efforts in the field of L-Arginine research. In 1983, there was virtually no published research in the field of L-Arginine research, and as a pioneer in this field, Dr. Allen had to seek research funds from friends and relatives in order to file Federal patents. That is no longer an issue, as Dr. Ann de Wees Allen’s patents have now generated over one $ Billion dollars, were featured on the front page of the Wall Street Journal, and named Breakthrough Product of the Year by Success magazine.


Breaking the code to genetic diseases, such as Sickle Cell and Thalassemia, leads the way to treating and curing global diseases that are tied to human DNA. In the future, genetic diseases may be treated by a simple pill, or in the case of Encode, a cherry drink. These treatments are free of side effects, and are referred to as “Edible Computer Chips ®” by the Encode team.

Graphic courtesy of: www.bio.davidson.edu

Copyright 2005 - 2011 Encode® Research Project